Skip to main content
main-content

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The TheraP trial

Michael Hofman explains why the TheraP study of LuPSMA versus cabazitaxel in men with metastatic castration-resistant prostate cancer is even more relevant in light of the recently reported CARD trial (4:24).

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits